We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A European Parliament committee is proposing that the European Commission promote transparency in private research to foster better access to medicines across the EU. Read More
The UK Court of Appeal affirmed an earlier ruling that invalidates Pfizer’s patent claims for Lyrica, saying generic versions will not lead to any infringement. Read More
The UK’s price watchdog is not recommending Janssen’s Imbruvica for the treatment of Waldenstrom's macroglobulinemia, a rare type of non-Hodgkin's lymphoma. Read More
Accessing a company’s policy on expanded access might be easier said than done, as most companies fail to post this information on their websites, a recent analysis found. Read More
The UK’s price watchdog is backing Celgene’s Otezla as a standalone or combined treatment for active psoriatic arthritis when other options are ineffective or not tolerated, provided the company discounts its price. Read More
A federal judge awarded Fresenius a preliminary injunction that blocks Fera Pharmaceuticals from marketing a levothyroxine sodium generic for the treatment of an underactive thyroid. Read More
A federal appellate court upheld a district court dismissal of Mylan’s antitrust case against Warner Chilcott and Mayne Pharmaceuticals, which alleged that the name-brand drugmakers modified their acne treatment Doryx to block generic competition and maintain a monopoly on the market. Read More
A federal judge rescinded his own verdict backing the FDA’s decision to not grant Ferring exclusivity for its bowel preparation drug Preponik, ruling that the agency must give the company five-years of retroactive exclusivity. Read More
Thirty-five states have filed an antitrust lawsuit against Indivior, alleging the company engaged in anticompetitive practices to block generics and inflate the price of the company’s opioid addiction treatment Suboxone. Read More
The United Nations High-Level Panel on Access to Medicine is proposing that governments rely on compulsory licenses to improve patient access to medicines in a highly anticipated report that has been met with dismay from industry. Read More